The Bill introduces several key measures to safeguard public health and streamline therapeutic goods regulation. Primarily, it strengthens the medicines shortages scheme by requiring sponsors to notify the Secretary of a decision to permanently discontinue a "reportable medicine" at least 12 months in advance, or as soon as practicable. As noted in the explanatory memo:
Early notification of discontinuation decisions by sponsors supports proactive planning, mitigates risks of shortages of alternative products and enhances continuity of care for patients, thereby improving public health outcomes.
The Bill also expands the Secretary's information-gathering powers, allowing them to require information about the availability or potential shortage of any approved medicine, not just those currently on the mandatory reporting list. This is intended to address supply issues for critical non-reportable items like certain intravenous fluids or diagnostic agents [Explanatory Memo page 12].
Furthermore, the Bill introduces a "common biologicals groups" power, allowing similar biological products to share a single entry in the Australian Register of Therapeutic Goods. This measure aims to reduce the regulatory and financial burden on industry by avoiding duplicative entries and annual charges [1]. Finally, the Bill moves search and inspection powers for clinical trial sites from delegated regulations into primary legislation to ensure that "powers that are intrusive and coercive in nature... should generally be conferred by primary legislation" [Explanatory Memo page 23].
The explanatory memo estimates this will result in a $0.2 million reduction in TGA revenue over three years from 2027–28.
The primary justification for this Bill is the significant improvement it offers to public health outcomes by providing health practitioners and patients with the lead time necessary to adapt to medicine discontinuations. By mandating a 12-month notice period, the Bill allows for the identification of alternative therapies and the updating of clinical protocols before a supply gap occurs, thereby protecting the continuity of care [Judgment].
From a legal standpoint, the Bill corrects a significant oversight by moving coercive entry and search powers related to clinical trials into primary legislation. This aligns with the principle that intrusive state powers should be subject to the highest level of parliamentary scrutiny rather than being buried in delegated regulations. Furthermore, the Bill promotes efficiency through the grouping of biologicals, which reduces the administrative overhead for innovative medical companies without compromising safety standards.
Finally, the Bill supports individual autonomy by ensuring that patients are not suddenly deprived of life-saving medications without warning. Providing the TGA with the power to request information on a broader range of medicines—such as IV fluids and diagnostic agents—ensures that the government can proactively manage the entire medical supply chain, rather than reacting only when a crisis is already underway [Judgment].
While the Bill's intentions are noble, it introduces significant risks and burdens that may be counterproductive. A major epistemic concern is the risk of stockpiling. As the explanatory memo itself acknowledges, earlier publication of discontinuation information can trigger panic-buying by patients and providers, which may actually accelerate a shortage and create immediate scarcity where none previously existed [Judgment].
From a propertarian perspective, the 12-month notice requirement may be commercially unfeasible for sponsors facing unforeseen manufacturing failures or global supply chain collapses. Forcing companies to maintain supply or report discontinuations a year in advance when they may only have weeks of visibility into their own raw material availability imposes an unrealistic regulatory burden that could discourage smaller players from entering the Australian market [Judgment].
Lastly, the expansion of search and inspection powers at clinical trial sites, even when moved to primary legislation, raises serious privacy concerns. The Bill allows authorised persons to enter premises and inspect records—including potentially sensitive health information of trial participants—without a warrant or prior consent. While the government argues these powers are necessary for safety, they represent a significant encroachment on the privacy of both the clinical trial staff and the participants, particularly when unannounced inspections are conducted without the traditional safeguards of judicial oversight.
2026-07-02
House of Representatives
Before Senate
Unspecified
Health, Disability and Ageing
Healthcare, Science / Technology, Consumer Protection